Deglycase-activity oriented screening to identify DJ-1 inhibitors
作者:Igor Maksimovic、Efrat Finkin-Groner、Yoshiyuki Fukase、Qingfei Zheng、Shan Sun、Mayako Michino、David J. Huggins、Robert W. Myers、Yael David
DOI:10.1039/d1md00062d
日期:——
Tracking the esterase activity of DJ-1 via a fluorescent-based scalable assay to uncover and develop candidates with enhanced potency.
通过基于荧光的可扩展测定方法跟踪DJ-1的酯酶活性,以发现并开发具有增强效力的候选物。
Synthesis of Azobenzenes from Quinone Acetals and Arylhydrazines
作者:M. Carmen Carreño、Gerardo Fernández Mudarra、Estíbaliz Merino、María Ribagorda
DOI:10.1021/jo0498011
日期:2004.5.1
Direct reaction between quinone bisacetals and arylhydrazines gives azobenzenes. The presence of catalytic amounts of cerium ammonium nitrate strongly accelerates the reaction. When the bisacetal has a substituent at the 2,5-cyclohexadiene framework, only one regioisomer is formed. The method represents a simple, mild, and novel synthetic access to differently substituted azocompounds in high to excellent
Enantiopure Guanidine Bases for Enantioselective Enone Epoxidations: 2, Cyclic Guanidines
作者:Richard J. Taylor、Julie C. McManus、Thorsten Genski、John S. Carey
DOI:10.1055/s-2003-37107
日期:——
A range of structurally and functionally varied enantiopure cyclic and bicyclic guanidines has been prepared and evaluated in the enantioselective epoxidation of 3-tert-butoxycarbonylamino-4,4-dimethoxycyclohexa-2,5-dien-1-one 1 using tert-butylhydroperoxide. Encouraging enantiomeric excesses were observed (up to 60%). Low enantiomeric excesses were also observed with 2-methylnaphthoquinone and trans-chalcone.
acid esters and (2-hydroxy-5-oxobicyclo [4.1.0] hept-3-en-3-yl) benzamide with TMSCl gave 7-membered ring compounds in good yields. The structure of the substituent at the C3 position of the cyclohexene ring is crucial for this ring expansion. The reaction mechanism is thought to involve the formation of a norcaradiene (bicyclo [4.1.0] hept-2,4-diene) structure and subsequent electrocyclic reaction.
[EN] INHIBITORS OF NF-KB<br/>[FR] INHIBITEURS DU FACTEUR NF-KB
申请人:PROFECTUS BIOSCIENCES INC
公开号:WO2010111460A1
公开(公告)日:2010-09-30
The invention relates to compounds of formulae (1) and (2), and pharmaceutically acceptable salts thereof for the treatment of cancer, inflammation, auto-immune diseases, diabetes and diabetic complications, infection, cardiovascular disease and ischemia-reperfusion injuries.